Safety Evaluation of Recombinant Human Interleukin-4
- 1 April 1997
- journal article
- Published by Elsevier in Clinical Immunology and Immunopathology
- Vol. 83 (1) , 12-14
- https://doi.org/10.1006/clin.1997.4304
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Safety Evaluation of Recombinant Human Interleukin-4Clinical Immunology and Immunopathology, 1997
- Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma modelCellular Immunology, 1995
- Intralesional Treatment of Established Murine Primary Renal Tumor With Interleukin-4: Localized Effect on Primary Tumor With no Impact on MetastasesJournal of Urology, 1995
- The eosinophil-mediated antitumor activity of interleukin-4Journal of Allergy and Clinical Immunology, 1994
- Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptorsInternational Journal of Cancer, 1994
- An Eosinophil-Dependent Mechanism for the Antitumor Effect of Interleukin-4Science, 1992
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- Interleukin-4: a prototypic immunoregulatory lymphokineBlood, 1991
- IL4 and IL5: The role of two multifunctional cytokines and their place in the network of cytokine interactionsBiotherapy, 1990
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989